Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 3/20 | 0.51 |
| ▸ | LCLAT1 | Q6UWP7 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 8/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15902246 | 0.84 | SORT1 (0.78) | SORT1SCN10AHDAC4HDAC6SCN8A | |
| SCHEMBL15902028 | 0.83 | SORT1 (0.57) | SORT1LCLAT1SCN10AHDAC4HDAC6 | |
| SCHEMBL15902152 | 0.82 | SORT1 (0.56) | SORT1SCN10AHDAC4HDAC6SCN8A | |
| SCHEMBL20638733 | 0.82 | SCN10A (0.56) | ABL1LCLAT1BRAFSCN10ANPC1 | |
| SCHEMBL15901600 | 0.77 | SORT1 (0.78) | SORT1SCN10AHDAC4HDAC6SCN8A | |
| SCHEMBL22941942 | 0.77 | SORT1 (0.58) | SORT1ABL1BRAFSCN10AHDAC4 | |
| SCHEMBL15901905 | 0.77 | SORT1 (0.57) | SORT1SCN10ASCN8ANPC1RAB9A | |
| SCHEMBL15902067 | 0.77 | SORT1 (0.55) | SORT1SCN10AHDAC4HDAC6NPC1 | |
| SCHEMBL15902053 | 0.76 | SORT1 (0.65) | SORT1SCN10AHDAC4HDAC6SCN8A | |
| SCHEMBL28921378 | 0.75 | SORT1 (0.56) | SORT1BRAFSCN10AHDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673864-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3865475-A1 | PROCESS FOR PREPARING PYRIDONE AMIDES WHICH ARE MODULATORS OF SODIUM CHANNELS AND INTERMEDIATE COMPOUNDS USED THEREIN | Vertex Pharmaceuticals Incorporated (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-108164457-B | Pyridone amides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20210047271-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-02-18 | — | — | US | disclosed |
| EP-3239134-B1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10738009-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190248745-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2019-08-15 | — | — | US | disclosed |
| US-10087143-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180016235-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-01-18 | — | — | US | disclosed |
| EP-3239134-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9758483-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-12 | — | — | US | disclosed |
| EP-2953931-B1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170037009-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2017-02-09 | — | — | US | disclosed |
| US-9393235-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2953931-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150246028-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-09-03 | — | — | US | disclosed |
| US-9051270-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014120808-A9 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2014120808-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20140213616-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016235-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
| US-20150246028-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
| US-20140213616-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
| US-10738009-B2 | Pyridone amides as modulators of sodium channels | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
| US-20170037009-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
| US-20210047271-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
| US-11673864-B2 | Pyridone amides as modulators of sodium channels | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
| US-10087143-B2 | Pyridone amides as modulators of sodium channels | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
| US-20190248745-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | SORT1 4300/4885ABL1 1065/4885LCLAT1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.